• The heart requires an uninterrupted supply of energy for contraction, and this energy is derived from oxidative metabolism of fuels. The product of oxidative metabolism is adenosine triphosphate (ATP).
• The heart requires an uninterrupted supply of energy for contraction, and this energy is derived from oxidative metabolism of fuels. The product of oxidative metabolism is adenosine triphosphate (ATP).
• The heart makes energy by oxidative phosphorylation of adenosine diphosphate (ADP). • In the postprandial state, and under resting conditions, long chain fatty acids and glucose are the main fuels for respiration.
• Inborn errors in myocardial fatty metabolism are increasingly recognized as causes of cardiomyopathy and sudden death in children.
• Myocardial metabolism is an integral part of the function of the heart, as both a consumer and a provider of energy.
• Energy transfer is impaired in the failing heart. Few cardiologists consider the heart a metabolic organ (the biochemistry of myocardial ischemia is a notable exception). Yet, energy substrate metabolism provides the energy currency needed for normal contractile function of the heart, and metabolic dysregulation is considered both cause and consequence of contractile dysfunction of the heart. This chapter reviews several metabolic principles that are relevant for the practicing cardiologist and are useful in the diagnosis and treatment of heart disease.
Like any organ of the mammalian body, the heart consists of a complex system of interactive proteins, purine bases, energy-providing compounds, membranes, and signal molecules, all of which are in a constant state of fl ux. In this dynamic system, the heart has retained its ability to adapt to a multitude of environmental changes, either by acutely changing fl ux through existing metabolic pathways to maintain its energy supply, 1, 2 or by chronically altering the synthesis of specifi c proteins of cardiac structure, function, and metabolism. [3] [4] [5] [6] [7] [8] 
Between Gene Expression and Energetics: Fuel Metabolism in Perspective
The heart requires an uninterrupted supply of energy for contraction. This energy is derived from the oxidative metabolism of fuels. Fuel metabolism, in turn, is regulated by the expression of enzymes and controlled by the energy requirements of the heart. The principle of metabolic fl ux has long been recognized. Early in the 20th century, substrate metabolism became the subject of intense research. 9 The product of oxidative metabolism is adenosine triphosphate (ATP). Like in any other organ of the body, in the heart it is impossible to separate function from metabolism. As shown in the simple scheme ( Fig. 50.1 ), a decrease in the fl ux of metabolic energy (e.g., with ischemia) results in a decrease in ATP production and, consequently, a decrease in contractile function. In contrast, an increase in contractile function (e.g., with inotropic stimulation) results in an increase in ATP turnover and an increase in oxygen consumption, which is a measure of energy utilization by the heart.
By measuring arteriovenous differences in the heart-lung preparation of the dog or in the human heart through 5 0 c h a p t e r 5 0 cannulation of the coronary sinus, early investigators 10, 11 have laid the foundation for our current understanding of myocardial substrate metabolism. The more recent reviews survey the knowledge gained through isolated heart preparations, isolated cell preparations, and isolated cell organelles. 5, [12] [13] [14] [15] [16] [17] Because factual information can be gleaned from these reviews, only principles of cardiac metabolism as they may be relevant to the patient with heart disease are reviewed here.
Since the classical biochemical era, our understanding of fuel metabolism in the heart has been greatly aided by introduction of new methods to assess metabolic activity in the intact, beating heart, such as nuclear magnetic resonance spectroscopy or magnetic resonance imaging (MRI), or in the heart in vivo, such as positron emission tomography (PET). A major feature of these new technologies is that they may permit a distinction between heart muscle that is reversibly dysfunctional and heart muscle that is irreversibly damaged.
Heart Muscle: Consumer and Provider of Energy
The goal of cardiac metabolism is to maintain a dynamic state of equilibrium for effi cient energy transfer in this highly specialized organ. In so doing, heart muscle converts chemical energy into physical energy. The physical energy of the heart consists of pump work (mechanical energy) that, in turn, distributes energy in the form of substrates and oxygen both to the heart itself and to the rest of the body. Here two important concepts must be considered. First, the heart is a "hot spot" of metabolic activity, continuously making and breaking ATP, the chemical energy available for conversion to mechanical energy at the contractile site. The greater the work output, the higher the rate of ATP turnover, the higher the rate of oxygen consumption, and the higher the rate of substrate utilization ( Fig. 50.1) . Second, when the heart's ability to convert chemical into mechanical energy is impaired for any reason, 18 the consequences manifest themselves as functional and metabolic derangements in the rest of the body, commonly referred to as heart failure. Because heart failure is a systemic disease that begins and ends with the heart, understanding the regulation of energy transfer in the heart provides important clues for understanding and treating heart failure. 19 The rate of ATP turnover in the heart is greater than the rate of ATP turnover in any other organ of the body, and this is often underestimated. A simple calculation, based on measurements of myocardial oxygen consumption, indicates that during the course of a 24-hour period, the human heart produces (and uses) 5 kg of ATP (i.e., more than 10 times its own weight and 1000 times the amount of ATP stored in the heart). Another comparison comes to mind. Although the human heart makes up only 0.5% of total body weight, it claims 4% of total cardiac output and 10% of the body's oxygen consumption. Lastly, it is important to remember that it is the rate of energy turnover, and not the tissue content of ATP, that determines myocardial energy metabolism. 14, [20] [21] [22] The heart makes energy by oxidative phosphorylation of adenosine diphosphate (ADP). Because of the high oxygen requirement, it is not surprising that the capillary density in heart muscle is far greater than in other organs (2500 capillaries/mm 2 vs. 400 capillaries/mm 2 in skeletal muscle) 23 and that heart muscle cells are fi lled with mitochondria, the cell organelles possessing the enzymes of oxidative metabolism ( Fig. 50.2) . A close correlation exists among mitochondrial volume fraction, heart rate, and total body oxygen consumption, with mitochondrial volume fractions ranging from 25% in humans to 38% in mice. 24 Heart muscle mitochondria are not only abundant, they also contain a far greater number of cristae (the location of respiratory chain enzymes) than do mitochondria of other organs, such as liver, brain, or skeletal muscle. 25 Energy transfer in biologic systems obeys the fi rst and second laws of thermodynamics as defi ned by Helmholtz in 1845. The fi rst law of thermodynamics states that within a closed system, energy can only be converted from one form into another. The second law of thermodynamics states that a process occurs spontaneously only if it is associated with an increase in randomness (or entropy) of the system. Defi ning the bewildering array of metabolic pathways in the cell depicted in wall charts and textbooks is the result of many years of painstaking biochemical research.
Metabolic Pathways: The Highways of Energy Transfer
In heart muscle, complex chemical reactions proceed rapidly at a relatively low temperature and at low substrate concentrations through enzyme-catalyzed pathways, an essential part of which are cycles (e.g., the citric acid cycle, the ATP cycle), because cycles have evolved as the most effi cient form of energy transfer. 13, 26 In addition, a few defi nitions may be useful.
A metabolic pathway is defi ned as a series of enzymecatalyzed reactions beginning with a fl ux-generating step (usually a reaction catalyzed by a nonequilibrium reaction or transport of the metabolite across a membrane) and ending with the removal of a product. 27, 28 Characteristic of most metabolic pathways is that once fl ux has been initiated, there is a rapid and concerted response of the entire pathway. In this system of fl ux, metabolite levels control enzyme activities and, in turn, enzyme activities control metabolite levels. It is important to distinguish between control and regulation of metabolism. Metabolic control is the power to change the state of metabolism in response to an external signal, whereas metabolic regulation is geared toward maintaining a constant internal state. 29 In such a system, large changes in the fl ux through metabolic pathways correspond to only very small changes in myocardial metabolite concentration. 30 Regulatory sites of metabolism, or pacemaker enzymes, 31 may become targets for the manipulation of metabolism with drugs. 32, 33 In the heart, the purpose of most enzyme-catalyzed reactions is catabolic. Substrates of high potential energy are broken down to products of lower potential energy. Synthetic or anabolic reactions, such as those serving protein, glycogen, or triglyceride synthesis, are quantitatively of lesser importance. In other words, heart muscle is endowed with an effi cient system of energy transfer that liberates energy locked in chemical bonds by the generation of reducing equivalents and their reaction with molecular oxygen in the mitochondrial electron transport chain. The main purpose of intermediary metabolism in normal heart muscle, therefore, is the production of reducing equivalents for ATP synthesis, in the course of which fuels are turned into carbon dioxide and water.
The breakdown of substrates can be divided into three stages ( Fig. 50.3 ). The fi rst stage consists of substrate uptake by the cell and of the metabolic pathways leading to acetyl coenzyme A (acetyl-CoA). The second stage consists of the oxidation of acetyl-CoA in the Krebs cycle. The third stage consists of the reaction of reducing equivalents with molecular oxygen in the respiratory chain, where electron transfer is coupled to rephosphorylation of ADP to ATP. Adenosine triphosphate production is tightly coupled to ATP utilization, and in the normal heart substrate oxidation is also tightly coupled to cardiac work. 1, 34, 35 An acute increase in workload of the isolated working rat heart results in an acute increase in myocardial oxygen consumption (Fig. 50.4 , measured) and CO 2 production (Fig. 50.4, predicted) , and the heart switches from fatty acids (oleate) to carbohydrates (glycogen, glucose, and lactate) as the main fuel for respiration (Fig. 50.5) . Reduced fl avin adenine dinucleotide (FADH 2 ) and reduced nicotinamide adenine dinucleotide (NADH) are generated, and the reducing equivalents enter the electron transport chain, producing an electrochemical gradient across the inner mitochondrial membrane that drives ATP synthesis in the presence of molecular oxygen.
In isolated mitochondria the rate of ATP production is driven by the extramitochondrial concentration of ADP (state 3 respiration). The exact mechanism by which respiration is coupled to energy expenditure in vivo, however, is not known. [36] [37] [38] But the effi cacy of oxidative phosphorylation for energy production is well established. For example, 1 mol of glucose, when oxidized, yields 36 mol of ATP, whereas the same amount of glucose yields only 2 mol of ATP when metabolized to lactate under anaerobic conditions.
There are two further aspects of cardiac metabolism that are often overlooked: the nutrition of the heart and endogenous substrates. Nutritional experiments (in the levels in the blood is still debated. 40 Furthermore, the focus on cholesterol has shifted attention away from the fact that the heart requires large amounts of foodstuffs to meet its energy requirements. Both quantity and quality of these foodstuffs vary greatly in the course of a day. Metabolically speaking, the heart does not differ from the body as a whole. It is an omnivore (i.e., an organ that has developed or retained its ability to oxidize a variety of different substrates). 41 The dietary advice for feeding the heart is the same as for feeding the body. Just as patients should not restrict fat and eat unrestricted carbohydrates, patients should not overly restrict carbohydrates and eat unrestricted amounts of fat. 42 The heart stores endogenous substrates such as glycogen and triglycerides in response to changes in the dietary state 43, 44 and the heart continuously synthesizes and degrades its own constituent proteins, 45, 46 a process that requires energy 47, 48 and is signifi cantly slowed by myocardial ischemia.
Substrate Competition and Metabolic Flexibility
In the postprandial state and under resting conditions, longchain fatty acids and glucose are the main fuels for respiration ( Fig. 50.6, top) . Fatty acids, glucose, lactate, ketone bodies, and, under certain circumstances, even amino acids compete with one another as fuels for respiration. As an omnivore, the heart readily switches from one substrate to another when it is stressed and carbohydrates become the main fuel for respiration ( Fig. 50.6 , bottom). Metabolic fl exibility is an inherent property of the normal heart. The microorganism Neurospora crassa) are at the beginning of the fundamental discovery that genes provide the blueprints for enzymes. 39 Today, nutrition is often confi ned to a single issue, and that is obesity and cholesterol. "Heart-healthy" diets have also focused heavily on cholesterol because of its role in the development of coronary artery disease, but even the correlation between dietary cholesterol and cholesterol relative predominance of a fuel for respiration depends on the arterial substrate concentration (which in the case of fatty acids, lactate, and ketone bodies can vary over a wide range) and on hormonal infl uences, workload, and oxygen supply. Stated simply, for a given environment the heart oxidizes the most effi cient substrate. When Bing 11 cannulated the coronary sinus and measured aortocoronary sinus differences in substrate concentrations across the heart, he observed a proportional relationship between arterial substrate concentration and substrate uptake by the heart under steady-state conditions, which changed with changes in the physiologic environment. Subsequent work by others 49 has established that the relative contribution of a substrate to the fuel for respiration depends on the physiologic state of the entire body. In the stressed heart in vivo the effi ciency of glucose as substrate exceeds the effi ciency of fatty acids as substrate by as much as 40%. 50 The normal mammalian heart readily switches from one substrate to another.
Tracing Metabolic Pathways: Molecular Imaging of the Heart
Tracing of metabolic pathways can be accomplished qualitatively owing to the development of new, nondestructive imaging techniques such as nuclear magnetic resonance spectroscopy and PET. Both techniques permit the assessment of regional metabolic processes in the beating heart both in vitro and in vivo. [51] [52] [53] [54] [55] [56] [57] [58] Analysis of energy-rich phosphates in the beating heart by nuclear magnetic resonance spectroscopy of phosphorus 31 ( 31 P) lends further support to the view that over a relatively wide range of work output, tissue content of ATP is not correlated with ATP turnover, as assessed by oxygen consumption or contractile performance of the heart. 59 The recent adaptation of isotopomer analysis of carbon 13 ( 13 C) natural abundance or 13 C-labeled compounds allows the analysis of fl ux through specifi c pathways, especially the Krebs citric acid cycle and glycogen turnover, to be studied quantitatively as serial spectra are obtained. 58, [60] [61] [62] Short-lived positron-emitting tracers have been so successful in their clinical application because they permit a visual assessment of regional differences in metabolic activity of the heart. 57, 63 Two types can be distinguished, and these are depicted in (Fig. 50.7 ). The fi rst approach entails uptake and retention of a tracer analogue, such as fl uorine 18 [ 18 F-]-2-deoxy, 2-fl uoroglucose (FDG). The second approach entails the uptake and clearance of 11 C tracers (fatty acids, glucose, or lactate) where the rapid phase of clearance from the tissue represents either β-oxidation and oxidation in the Krebs citric acid cycle (e.g., in the case of long-chain fatty acids) or oxidation in the Krebs citric acid cycle alone (e.g., in the case of acetate) 63 . Uptake and retention of the tracer analogue FDG increase linearly with time, 64 whereas the clearance of a labeled fatty acid after an initial peak in tissue activity is biexponential. 63, 65, 66 Both types of approaches have been used clinically to assess substrate metabolism in normal and ischemic myocardium. Enhanced glucose uptake (assessed with FDG) is used to identify reversible ischemia in "hibernating" myocardium ( Fig. 50.8 ) where there is a mismatch between fl ow (decreased) and metabolic activity (increased). The mismatch of perfusion and metabolism is an indicator of myocardial viability. 67 However, a word of caution is in order. Quantitative assessment of myocardial glucose uptake by FDG depends on a correction factor, the lumped constant of Sokoloff. 68 The lumped constant is not a true constant, because the tracer/ tracee ratio (uptake of FDG versus uptake of glucose) changes under non-steady-state conditions. It decreases with insulin 69 and with reperfusion after low-fl ow ischemia 70 which would result in a spurious underestimation of glucose uptake unless a model of variable lumped constants is taken into account. 71 Imaging of myocardial metabolism with [ 11 C] tracers circumvents these shortcomings. 63 Indeed, this method has shown that patients with idiopathic dilated cardiomyopathy exhibit changes in substrate preference characterized by decreased fatty acid metabolism and increased glucose metabolism 72 in It is important to distinguish between "uptake and clearance" and "uptake and retention," because the time-activity curves differ substantially. keeping with the constitutive expression of the fetal metabolic gene program in the failing human heart.
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Metabolism of the Major Energy-Providing Substrates
Why does the heart use different fuels to make energy? Why is it important to know metabolic pathways in detail? The following analogy may be useful to answer these questions. Metabolic pathways can be likened to a power grid, and the heart can be likened to a light bulb. Fuels are the various sources of energy (coal, water, natural gas, nuclear fi ssion) that are all converted to electricity. A simple explanation for this redundancy is that fuels are used whenever they are most readily available. All fuels are converted to the same form of energy. In short, for a given environment the heart uses the most effi cient source of energy, and this is the result of tight regulation in metabolic pathways.
Carbohydrates
Carbohydrate fuels for the heart are glucose, lactate, and glycogen. Although long-chain fatty acids are normally the predominant fuel for energy production in the mammalian heart, carbohydrates are the fuel for the fetal heart 74 and for the stressed adult heart in the state of exercise. 75 Glucose serves as the heart's "backup" fuel. The reasons for such a "hierarchy" of fuels can be found in a number of observations: (1) In the normal, that is, the nondiabetic, mammalian organism, glucose levels in the blood are tightly regulated at around 5 mM or (90 mg%). (2) When we exercise and blood lactate levels rise, lactate replaces all other substrates as fuel for respiration of the heart. 75 (3) When the normal heart is stressed, it oxidizes fi rst glycogen, then glucose and lactate. 1, 76 (4) Glucose is an anaplerotic substrate for the Krebs cycle, 35, 77 and glucose is essential for the initiation of fatty acid oxidation in heart. 78 Hypoglycemic newborns develop cardiomegaly and heart failure, which are both completely reversible with the administration of glucose. 79 Furthermore, isotopic tracer studies have demonstrated that the normal human heart produces lactate at the same time it oxidizes lactate, 1, 80 and that it takes up glucose to form glycogen when in the fasted, resting state. 77, 81 It appears that a large portion of exogenous glucose is shunted fi rst into glycogen before it is oxidized. 82, 83 Glucose and lactate extraction by the heart in vitro and in vivo increases with an increase in workload, even in the presence of competing substrates. 35, 84 This observation is of interest in view of the importance of pyruvate, which is the common metabolic product of glucose, glycogen, and lactate. The main point is that pyruvate provides both acetyl-CoA (C 2 units) and oxaloacetate (C 4 units) for the Krebs citric acid cycle.
Regulatory Sites of Glucose Metabolism
There are three energy-yielding stages of glucose metabolism: the glycolytic pathway leading to pyruvate, oxaloacetate, and lactate; the Krebs cycle; and the respiratory chain. Each state is regulated by its own set of checkpoints, so that overall fl ux through the pathways (which may be assessed externally on a second-by-second time scale with the glucose tracer analogue FDG) 64 proceeds at a rate just suffi cient to satisfy the heart's beat-to-beat needs for the fi nal product, ATP. We discuss the regulatory sites of metabolism in more detail because dysregulation of one of these steps can affect the rate and effi cacy of energy transfer and, hence, contractile function of the heart.
Glucose Transport and Phosphorylation
The fi rst major regulatory site of the glycolytic pathway is glucose uptake. Glucose uptake is stereospecifi c and saturable. It follows classical Michaelis-Menten kinetics, and early investigators already deduced that active glucose transporters are membrane-associated proteins. The transport of glucose occurs along a steep concentration gradient and is regulated by specifi c transporters. 85 Stereospecifi city of the transporter for sugars of the carbon confi guration is not matched by the same degree of selectivity, and various tracer analogues, including 2-deoxyglucose and FDG, are transported in the same way as glucose.
Glucose transport, the rate-limiting step in myocardial glucose utilization, 86 is carried out by facilitative glucose transporters. The family of glucose transporters (GLUTs) is conserved over a wide range of organisms, suggesting a common evolutionary origin. [87] [88] [89] [90] GLUT-1 and GLUT-4 are the major glucose transporter isoforms expressed in the heart. 73, 91 GLUT-4, the insulin-sensitive transporter, is also found in skeletal muscle and in adipose tissue. 87 Heart muscle is an insulin-sensitive organ. 13 Insulin is considered an "endogenous cardioprotector" 92 because, in addition to promoting glucose uptake, insulin has a multitude of cellular and hemodynamic effects. 93 Recruitment of GLUT-4 from a microsomal cytosolic pool to the sarcolemma by insulin (or ischemia or adrenergic stimulation) [94] [95] [96] [97] increases the maximal velocity of glucose transport. α-Adrenergic stimulation uses the same signaling pathway as insulin to promote glucose uptake, 98 whereas the effects of ischemia, β-receptor stimulation, and insulin on glucose uptake are additive. 99 In addition to GLUT-4, the cardiomyocyte expresses the GLUT-1 transporter isoform, which is presumably independent of insulin regulation and predominates in fetal, hypertrophied, atrophied, and failing myocardium. 73, 88, 100 GLUT-1 is the fi rst gene whose transcription is dually stimulated in response to hypoxia and inhibition of oxidative phosphorylation, 101 and overexpression of GLUT-1 prevents the functional decline of the hypertrophied heart. 102 Both transporters have a Michaelis' constant (K m ) for glucose (i.e., the concentration at which the rate of glucose transport is half maximal) that is in the range of plasma glucose concentrations under fasting conditions. 103 The normal heart also expresses a low amount of GLUT-3, which has a K m below the normal plasma glucose concentration. 104 A number of novel GLUTs have been identifi ed in heart muscle, including GLUT-8, GLUT-11, and GLUT-12. 105 The role of these proteins in heart muscle is not yet defi ned.
Cardiac work and substrate availability, as well as plasma glucose and insulin concentrations, are important factors determining glucose uptake. 106 For example, myocardial glucose uptake is also determined by the dietary state per se, 107 by oxygen availability 82, 108, 109 and by hormones, such as catecholamines, growth hormone, and cortisol, which, in addition to insulin and glucagons, may affect either K m or maximal velocity (V max ) of glucose transport. The role of insulin signaling in the heart is complex and is intertwined with cardiac growth and development. 110 Phosphorylation of glucose by hexokinase becomes rate limiting for glycolysis at high rates of glucose transport. Rates of glucose phosphorylation measured in vitro are more than twice as high as the maximal measured rates of glucose utilization by the heart at a physiologic workload and with glucose as the only substrate. 111 Some evidence suggests that glucose, once inside the cell and phosphorylated, may preferentially enter the glycogen pool rather than the glycolytic pathway. 13, 83, 112 The intracellular glucose concentration of heart muscle rises during starvation, in diabetes, and with the concomitant oxidation of fatty acids, ketone bodies, or lactate, which indicates inhibition of the phosphorylation step. This is most likely to be due to accumulation of glucose-6-phosphate.
Glucose-6-phosphate is the substrate for several distinct enzyme systems. These systems include (1) degradation via the Embden-Meyerhof pathway (also termed the glycolytic pathway when it entails metabolism of glucose to lactate only); (2) conversion to glycogen via the glycogen synthase reaction; (3) metabolism (oxidation) via the pentosephosphate pathway, which yields ribose and the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) 113 ; and (4) entry into the hexosamine biosynthetic pathway. 114 The latter two pathways are of quantitatively lesser importance in heart muscle than are the former two. Of note is that most of these pathways are not available to the tracer analogue FDG 6-phosphate, which may, however, become a substrate for glycogen synthesis. 115 Hence, the commonly used tracer analogue FDG traces glucose uptake and phosphorylation, but it lacks specifi city with regard to the metabolic fate of glucose inside the cell.
Glycogen
The study of the pathways of glycogen synthesis and degradation in liver and muscle has contributed more to the understanding of enzyme regulation and the molecular basis of hormone action than any other known system of metabolic control. 116 It was in this system that the fi rst example for the control of enzyme activity by an allosteric regulator [activation of phosphorylase by adenosine monophosphate (AMP)] was described, 117 enzyme regulation by covalent modifi cation was discovered, 118 and the molecular basis of hormone action by signal transduction was elucidated through the discovery of cyclic adenosine monophosphate (cAMP). 119 The role of glycogen in the heart is still not completely understood. 120 The vast amount of glycogen in fetal cardiac muscle allows the heart to maintain its contractile activity in the face of severe hypoxia 121 during birth. One may speculate that the high concentration of glycogen in the specialized conduction system of the heart, fi rst described by Aschoff 122 at the beginning of the 20th century, may exert a protective effect against ischemia. Lastly, glycogen and glycogen phosphorylase are also closely associated with the sarcoplasmic reticulum, 123 and in skeletal muscle decreased glycogen content is closely associated with a reduction in force, Ca 2+ release from the sarcoplasmic reticulum, and contractile protein function. 124 Glycogen synthesis and degradation occur in two separate pathways. The combined effects of protein phosphorylation and dephosphorylation on glycogen synthase and phosphorylase provide an interlocking system by which hormones (such as epinephrine) and mechanical activity (through Ca 2+ ) can control the net fl ux of glucose 1-P into and out of the intracellular glycogen stores. 62, 125 Epinephrine-induced cAMP formation promotes protein phosphorylation and simultaneously inhibits glycogen synthesis while stimulating glycogen breakdown, whereas stimulation of protein dephosphorylation shifts the balance toward glycogen synthesis. Although the interaction of the enzymes glycogen breakdown and synthesis is more complex than this simple mechanism suggests, 126 the concept of a continuous turnover of the myocardial glycogen pool is relatively easy to grasp.
Excessive rates of glycogen breakdown during ischemia are thought to be deleterious for the recovery of contractile function because of the accumulation of lactate. However, the heart subjected to low-fl ow ischemia continues to synthesize glycogen, 127, 128 and enhanced glycogen stores (and with them, high rates of glycogen breakdown) improve contractile function in the ischemic and reperfused myocardium, [129] [130] [131] [132] [133] in the stressed myocardium, 134 and in the ischemic heart. [135] [136] [137] The role of glycogen in conveying ischemia tolerance is seen most dramatically in amphibian myocardium, which is particularly rich in this compound. 138 
Glycolysis
Glucose is unique among substrates in its ability to provide a small, but signifi cant, amount of ATP through substratelevel phosphorylation in the glycolytic pathway. This occurs especially in the setting of hypoxia and ischemia when fl ux through the glycolytic pathway is enhanced, resulting in the formation of lactate as well as alanine. 139 Other stimulants of fl ux through the glycolytic pathway are increases in cardiac work, either acutely with exercise, 1, 84 or chronically with pressure overload without 140 or with hypertrophy. 141, 142 Both hypertrophy and atrophy are associated with increased glucose oxidation rates but decreased insulin responsiveness of the heart. 143 Enhanced glycolytic fl ux lessens ischemic tissue damage. 136, 144 Although it is thought that the accumulation of glycolytic products may worsen the effects of ischemia 145 and acute hyperglycemia may abolish ischemic preconditioning in vivo, 146 provision of glucose together with insulin and potassium improves contractile function in the acutely ischemic, reperfused myocardium. [147] [148] [149] The inotropic effect of insulin in the postischemic heart is additive to epinephrine and coupled to enhanced glucose uptake. 150 Glycolysis from extracellular glucose (and no other metabolic pathway) protects cardiac myocytes from hypoxic injury and subsequent apoptosis. 151 The fi rst step committing glucose to the glycolytic pathway is 6-phospho-fructo-1-kinase (PFK-1), which catalyzes the phosphorylation of fructose 6-phosphate to fructose 1,6-bisphosphate. Because of the complex allosteric regulation of PFK, this is a rate-limiting step (pacemaker enzyme) for glycolysis. 152 Adenosine triphosphate, citrate, and protons are negative allosteric effectors, whereas AMP and fructose 1,6-bisphosphate are positive effectors. [153] [154] [155] Fructose 2,6-bisphosphate is the main activator of PFK-1 in normoxic heart.
Further down in the glycolytic pathway, the oxidation of the triose-phosphate glyceraldehydes 3-phosphate to 1,3-diphosphoglycerate couples in the energy-conserving step in the glycolytic pathway that leads to the nonoxidative formation of ATP. The reaction is thought to be at near equilibrium. However, under conditions of high cardiac work 156 or ischemia, 157 when PFK becomes strongly activated, glycolysis is controlled further downstream, at the triose-phosphate dehydrogenase step.
Pyruvate at the Crossroads: Oxidation Carboxylation, Reduction, and Transamination Just as the fi rst committed intermediate of glycolytic pathway, glucose-6-phosphate, is at a branch point where several enzymes compete for it as substrate, so is the last committed intermediate, pyruvate. In heart muscle, pyruvate can be reduced to lactate (which completes the glycolytic pathway), transaminated to alanine, 139 carboxylated to oxaloacetate or malate, 158, 159 or, most importantly, oxidized to acetyl-CoA. Lactate and most of the alanine are formed in the cytosol by near-equilibrium reactions, and both metabolites may be washed out from the cell. In well-oxygenated, working heart muscle, however, the bulk of pyruvate enters the mitochondrion. A specifi c carrier exists for transport of pyruvate into the mitochondrial matrix, as it has been most clearly demonstrated with the inhibitor 4-hydroxy-α-cyanocinnamate. 160 Inside the mitochondrial matrix, pyruvate can be either decarboxylated to acetyl-CoA or carboxylated to oxaloacetate. 159 The capture of metabolically produced carbon dioxide from the pyruvate dehydrogenase reaction to form oxaloacetate provides one example of the effi cient use of one substrate supplying two precursors for citrate synthesis and effi cient recycling of carbon dioxide.
Oxidative decarboxylation of pyruvate assumes a central position in the regulation of fuel supply to the heart. A system of intricate control mechanisms governs both activation and inactivation of the pyruvate dehydrogenase complex (PDC). 161 The conversion of pyruvate to acetyl-CoA requires the sequential action of three different enzymes: pyruvate dehydrogenase, dihydrolipoyl transacetylase, and dihydrolipoyl dehydrogenase. The reaction also requires fi ve different coenzymes or prosthetic groups: thiamine pyrophosphate, lipoic acid, uncombined sulfhydryl coenzyme A (CoA-SH), fl avin adenine dinucleotide (FAD + ), and nicotinamide adenine dinucleotide (NAD + ). These enzymes and coenzymes are organized into a multi-enzyme cluster.
Much work was done in the 1970s on the regulation of PDC by covalent modifi cation through a phosphorylation and dephosphorylation cycle. Multisite phosphorylation of the pyruvate dehydrogenase component of the complex provides an indirect means by which the entire complex is regulated by the relative activities of the PDC kinase and phosphatase reactions. Like most mammalian tissues, heart muscle possesses both active (dephosphorylated) and inactive (phosphorylated) dehydrogenase. Most of the known effectors of the phosphorylation-dephosphorylation cycle are also effectors of the kinase reaction. Of the metabolite pairs ATP-ADP, acetyl-CoA-CoA-SH, NADH-NAD + , and lactate-pyruvate, the fi rst member either activates the kinase or serves as substrate, and the second member inhibits the enzyme. Ca 2+ and Mg 2+ both inhibit the kinase and activate the phosphatase reaction (i.e., lead to PDC activation). The effects of fatty acids or ketone body oxidation are likely to be mediated by the increase in acetyl-CoA because of the primary effect or the inhibition-inactivation of PDC by fatty acids or ketone bodies in the acetyl-CoA-CoA-SH ratio. 162 Conversely, an increase in cardiac work may inhibit the PDC kinase owing to a decrease in NADH, acetyl-CoA, and ATP, leading to activation of PDC. 163 
Fatty Acids
Fatty acids, esterifi ed as triglycerides, represent the body's main fuel reserve. Because oxidation of long-chain fatty acids releases more than six times as much energy as the oxidation of an equal mass of glucose, fatty acids represent the predominant energy reserve for the body and fuel for respiration in heart muscle. In spite of their preeminence as a source for energy, fatty acids are the only fuel capable of uncoupling oxidative phosphorylation. 164, 165 This mechanism lowers the effi ciency of fatty acids as energy substrates. In contrast to glucose and glycogen, fatty acids require oxygen for their catabolism.
The predominant forms of fatty acids in the bloodstream are the monounsaturated long-chain fatty acid oleate (C 18:1 ) and the saturated fatty acid palmitate (C 16:0 ). The pathway of long-chain fatty acid oxidation starts with the liberation of fatty acids from triglycerides and ends with the entry of acetyl-CoA into the citric acid cycle. Free fatty acids (FFAs) of any chain length cross the plasma membrane with the help of carrier proteins, which have been cloned and expressed in a variety of systems. 166 In the cytosol, longchain fatty acids are bound by a heart-specifi c fatty acidbinding protein (h-FABP), [167] [168] [169] which ushers long-chain fatty acids from the cytosol toward the oxidation pathway. 170 Bound fatty acids are activated on the outer mitochondrial membrane by the enzyme fatty acyl-CoA synthetase and esterifi cation with CoA-SH to form fatty-acyl coenzyme A (acyl-CoA). Metabolism of long-chain fatty acids continues with fatty acyl transfer to carnitine, transport into the mitochondria in exchange for carnitine, reesterifi cation with CoA-SH, β-oxidation, and fi nally, oxidation of acetyl-CoA. A variable amount of FFA taken up by heart muscle is esterifi ed with glycerol in the cytosol to form triglycerides. Therefore, the fatty acyl-CoA formed on the outer mitochondrial membrane has two possible fates: either oxidation via the citric acid cycle in the mitochondria or conversion to triglycerides in the cytosol. Which pathway is taken depends on the rate of transfer of long-chain fatty acyl-CoA across the inner mitochondrial membrane and on the rate of esterifi cation in the cytosol. Increased net triglyceride synthesis by the heart has been observed with starvation, diabetes, ischemia, and in heart failure. 171 It is not known whether increased triglyceride levels are the result of increased rates of esterifi cation or a decreased rate of lipolysis. 172 Carnitine Palmitoyl Transferase, Malonyl-CoA Before the acyl group can be oxidized it must be moved from the outer mitochondrial membrane into the mitochondrion. Transfer on long-chain fatty acyl-CoA into mitochondria is rate limiting for β-oxidation of long-chain fatty acids and requires a three-step membrane transport process. The fi rst step in this sequence is the transfer of the acyl group from CoA to carnitine, catalyzed by the enzyme carnitine palmitoyl transferase I (CPT I).
The CPT I system is inhibited by physiologic concentrations of malonyl-CoA, the product of acetyl-CoA carboxylation, and was fi rst characterized in the liver, where malonyl-CoA serves as a signal regulating the relative rates of fatty acid oxidation, ketogenesis, and triglyceride synthesis. 173 In a beautiful system of checks and balances malonylCoA also is the fi rst step in the pathway for de novo fatty acid synthesis. Although the heart is not a lipogenic organ, it contains malonyl-CoA, 174 and the inhibition of cardiac CPT I by malonyl-CoA has been well documented. 175 A tissuespecifi c acetyl-CoA carboxylase has been identifi ed for heart muscle, 176 and so has malonyl-CoA decarboxylase. [177] [178] [179] There is at least indirect evidence that malonyl-CoA plays an important role in substrate competition between fatty acids and glucose. Malonyl-CoA levels are controlled by its rates of synthesis [via acetyl-CoA carboxylase (ACC)] and its rate of degradation [via malonyl-CoA decarboxylase (MCD)]. Because of the importance of malonyl-CoA for the regulation of fatty acid oxidation, the regulation of ACC and MCD has been intensely investigated. Specifi cally, ACC is inhibited by phosphorylation through AMP kinase, a protein kinase that is activated when ATP levels fall and AMP levels rise in the myocyte. This results in lower malonyl-CoA levels and increased rates of fatty acid oxidations; hence, AMP kinase has also been termed the "fuel gauge" of the cell. 180 Also, in the isolated, perfused, working rat heart, glucose suppresses the oxidation of oleate. 35 It is also worth noting that ischemia reverses the inhibition of CPT I by malonyl-CoA, most probably through a modifi cation in protein folding, thus making available increased amounts of palmitoyl-carnitine for oxidation on reperfusion. 181 The carnitine-acyl unit traverses the inner mitochondrial membrane and is transferred to CoA-SH inside the mitochondrial matrix by a second carnitine acyl-CoA transferase (CPT II) located in the inner surface of the inner mitochondrial membrane. Once inside the mitochondria, acyl-CoA is committed to oxidation by the system of β-oxidation. The β-oxidation pathway is controlled by fl uctuations in the concentrations of substrates (acyl-CoA, NAD + , and FAD + ) 182 or, expressed in more physiologic terms, by workload and oxygen supply of the heart. It is not yet clear how the rate of oxidation of FFA in the intact heart is related to citric acid cycle activity and the rate of oxidative phosphorylation. However, it is clear that fatty acid oxidation is arrested by ischemia and that the accumulation of long-chain acyl-CoA esters in ischemia inhibits the adenine nucleotide translocase in mitochondria. 183 This inhibition provides a possible explanation for contractile dysfunction.
In the liver, and most probably also in heart muscle, CPT I is the regulatory site for fatty acid oxidation, with high concentrations of malonyl-CoA acting as an inhibitor of the enzyme during the carbohydrate-fed state. To explore the gene regulatory mechanisms involved in the metabolic control of long-chain fatty acid oxidation in the heart, the expression of muscle-type CPT-1 (mCPT-1) was characterized in primary cardiac myocytes after incubation with oleate, which regulates mCPT-1 expression via the peroxisome proliferators-activated receptor-α (PPAR-α) 184 ; PPAR-α is a nuclear receptor family with multiple functions that is currently attracting the attention of many investigators and the pharmaceutical industry. 185 Malonyl-CoA decarboxylase (MCD) is transcriptionally regulated by PPAR-α, 179 and MCD inhibition protects the ischemic heart most likely by inhibiting fatty acid oxidation. 186 
Transcriptional Regulation of Myocardial Fatty Acid Metabolism
One way by which the heart responds to increased plasma fatty acid levels is by increasing the expression of various proteins involved in fatty acid utilization. 179, 184, [187] [188] [189] The mechanism by which fatty acids activate the transcription of these genes is through activation of the nuclear receptor PPAR-α, which heterodimerizes with 9-cis retinoic acid receptor (RXR) and activates the transcription of genes whose promoter contains the PPAR response element (PPRE) (Fig.  50.9 ). Of the cofactors that bind to the PPAR-α/RXR heterodimer, PCG-1α is highly expressed in the heart 190, 191 and plays a key role in mitochondrial biogenesis. 7 
Defective Fatty Acid Metabolism as a Cause of Heart Failure
Inborn errors in myocardial fatty acid metabolism are increasingly recognized as causes of cardiomyopathy and sudden death in children. [192] [193] [194] Defects at nearly every step of the fatty acid oxidation pathway have been identifi ed. 195 In recent years the advent of tandem mass spectrometry has greatly advanced the screening for metabolic cardiomyopathies. 194 The analysis of acylcarnitines in a dried blood spot rapidly provides a diagnosis in patients in whom an inherited metabolic disease is considered, and algorithms exist for the laboratory diagnosis of metabolic diseases presenting with cardiomyopathy. 196 The most common group of inherited defects involves the acyl-CoA dehydrogenase enzyme family, which catalyzes the initial reactions in mitochondrial β-oxidation of fatty acids. 197, 198 In general, enzymatic defects involving long-and very-long-chain fatty acids (C 14 or greater) or defects in cellular carnitine import of enzymes involved in the carnitine shuttle cause more severe clinical diseases, including cardiomyopathy, heart failure, and sudden death than with defects involving the metabolism of shorter-chain fatty acids. 199 Impaired β-oxidation and accumulation of triglycerides in cardiomyocytes are hallmarks of contractile failing of the heart from obese Zucker rats. 200 In Zucker diabetic fatty rats, lipotoxicity and contractile dysfunction are reversed by the administration of insulin sensitizing agents. 201, 202 Clinical manifestations of inherited defects in fatty acid metabolism range from fasting hypoglycemia to frank cardiomyopathy or sudden death, most likely due to the accumulation of long-chain acyl-carnitines. 203, 204 A defi nitive diagnosis is not always easy because there is no correlation between in vitro enzyme assays in fi broblasts and clinical manifestations. 205 Although of rare incidence, systemic carnitine defi ciency presents as familial endocardial fi broelastosis, which is associated with mitochondrial substrate deprivation and myocardial triglyceride accumulation. 206 As in experimental diphtheric cardiomyopathy, 207 the abnormality is reversible with the administration of L-carnitine, and it has therefore been recommended that plasma carnitine levels in all patients who present with familial cardiomyopathy be determined. 206 A chronic cardiomyopathy has been described in children who have a defect in carnitine uptake. 208 
Ketone Bodies
The ketone bodies, acetoacetate and β-hydroxybutyrate, are produced by the liver when β-oxidation of FFAs exceeds the liver's capacity for complete oxidation in the citric acid cycle. When released into the bloodstream, "predigested fatty acids" have ready access to the enzymes of the citric acid cycle in the heart. Thus, ketone bodies share in the supply of acetyl-CoA for energy production in heart muscle, 209 but compared with the complexity of glucose and long-chain fatty acid metabolism, the metabolism of ketone bodies is simple and not subject to regulation.
Features of ketone body metabolism include their concentration-dependent linear uptake in vivo 210 and the activation of acetoacetate to acetoacetyl-CoA by succinyl-CoA, which itself is a citric acid cycle intermediate. The enzymes that degrade β-hydroxybutyrate and acetoacetate to acetylCoA, β-hydroxybutyrate dehydrogenase, 3-oxoacid-CoA transferase, and acetoacetyl-CoA thiolase are of high activity in heart. 209 The ability of the heart to oxidize ketone bodies may constitute a buffer against qualitative changes in substrate supply when the relative proportions of oxidizable fuel are shifting as a result of changes in the dietary or hormonal state of the body. Even in physiologic situations, such as short-term starvation or exercise, ketone body concentrations in the plasma can rise by up to 50-fold. 211 When present as the only exogenous substrate for rat heart, ketone bodies do not sustain the full work output of the heart in vivo, 212 and their rate of oxidation in the citric acid cycle is insuffi cient to meet the energy needs of the heart in vitro. 35 This relative inhibition of the citric acid cycle occurs at the level of 2-oxoglutarate dehydrogenase and provides the fi rst demonstration of a defect in metabolism that causes reversible contractile dysfunction in the heart. 35, 213 The inhibition is caused by sequestration of the enzyme's cofactor CoA SH, which is bound in the form of its thioester acetyl-CoA and as acetoacetyl-CoA, and is therefore not available for the reaction in the citric acid cycle. 77 Observations in the isolated working rat heart perfused with ketone bodies have identifi ed hitherto unknown mechanisms of the control of cardiac function by substrate metabolism. These include the reversible inhibition of contractile function by inhibited fl ux through the Krebs citric acid cycle, the operational control of substrate fl ux through citric acid cycle spans, and the importance of anaplerosis (i.e., the provision of oxaloacetate or other citric acid cycle intermediates in addition to acetyl-CoA for citrate synthesis for normal contractile function of the heart). 159 The importance of anaplerosis of the Krebs cycle in heart muscle is also suggested by improved cardiac function with propionyl-Lcarnitine 214 and by stable isotope experiments using 13 C-nuclear magnetic resonance spectroscopy, 215 supporting the principle that the heart functions best when it oxidizes several substrates simultaneously. Pyruvate carboxylation in the in vivo heart accounts for at least 3% to 6% of citric acid cycle fl ux despite considerable variations in fl ux through pyruvate decarboxylase. 216 
Amino Acids
In addition to their role as "building blocks" of myocardial proteins, amino acids are also an integral part of myocardial energy metabolism. Most amino acids are either degraded or synthesized by heart muscle (e.g., glutamate, glutamine, aspartate, alanine, leucine), whereas others are not metabolized at all (e.g., phenylalanine, tyrosine).
The release of transaminases serves as biomarker of irreversible myocardial injury and the diagnosis of myocardial infarction. Under physiologic circumstances one of the main functions of transaminases in heart muscle is the provision of carbon skeletons for the citric acid cycle. 217 Furthermore, the amino acids aspartate and glutamate play an important role in the transfer of reducing equivalents across the mitochondrial membrane for oxidation of cytosolic NADH by the mitochondrial electron transport chain. In the malateaspartate cycle, cytosolic NADH, which cannot cross the inner mitochondrial membrane, is oxidized by the reduction of oxaloacetate to malate. Malate enters the mitochondrion and is oxidized to oxaloacetate, which is transaminated with glutamate to form 2-oxoglutarate and aspartate. The aspartate and 2-oxoglutarate leave the mitochondrion. Transmission of these metabolites regenerates oxaloacetate and glutamate in the cytosol, the net effect being a transfer of hydrogen ions across the mitochondrial membrane. [218] [219] [220] A second postulated function for the malate-aspartate shuttle is the delivery of intermediates (malate) to the citric acid cycle, serving as a modulator of cycle activity. 221 Myocardial amino acid metabolism during hypoxia, ischemia, and reperfusion has been the subject of a number of studies in the intact and isolated heart muscle. [222] [223] [224] The amino acid alanine is like lactate, an end product of anaerobic glucose breakdown, arising through transamination of glutamate in this reaction:
Whereas alanine leaves the cell, 2-oxoglutarate is further metabolized and decarboxylated to succinate via substrate level phosphorylation in the citric acid cycle 225 : 2-oxoglutarate + NAD + + GDP + P i → Succinate + CO 2 + NADH 2 + GTP where NAD + is nicotinamide adenine dinucleotide, GDP is guanosine diphosphate, P i is inorganic phosphate, and NADH 2 is reduced nicotinamide adenine dinucleotide. Since guanosine triphosphate (GTP) is readily transphosphorylated to ATP, this reaction is a source of anaerobic energy independent of lactate formation. Enhanced glutamate uptake in vivo has been shown by nitrogen 13 ( 13 N) accumulation from labeled glutamate in ischemic heart muscle, 226 and glutamate enrichment has become a successful strategy to lessen the effects of ischemia with blood cardioplegia. 227 However, the neurotoxicity of glutamate precludes its systemic administration.
Metabolic Signals of Cardiac Growth and Gene Expression
The heart's response to changes in its environment is linked to a complex network of interconnecting signal transduction cascades. 228 At fi rst glance it seems that signals arising from intermediary metabolism may have no place in such a scheme. However, we have reviewed evidence in support of the hypothesis that alterations in metabolic fl ux within the cardiomyocyte create essential signals for the adaptation of the heart, 229 because many of the acute changes in metabolic fl ux are brought about by the same signal transduction cascades believed to be involved in the adaptation to the heart's environment, e.g., phosphatidylinositol 3-kinase, 98 diacylglycerol, Ca 2+ , and protein kinase C (PKC). 126 Thus, metabolic signals are an integral part of cardiac adaptation. 229 Here we briefl y mention some of the basic concepts of fatty acid and of glucose regulated gene expression.
As already discussed in detail, fatty acids are the predominant fuel for respiration in the postnatal heart. In addition to their role as energy providing substrates, fatty acids serve as mediators of signal transduction and as ligands for the nuclear transcription factor PPAR-α. Changes in substrate supply to the heart are refl ected in changes of fl ux through fatty acid metabolizing pathways. Levels of intracellular long-chain fatty acids are tightly regulated, so that there is a balance between transport of fatty acids from the interstitial space into the cell and transport from the cytosol into mitochondria and subsequent oxidation. This balance is regulated mainly by malonyl-CoA, which inhibits transport of fatty acids into mitochondria. Prolonged inhibition of CPT I promotes intramyocellular lipid accumulation and insulin resistance in rats. 230 Conversely, leptin inhibits malonylCoA synthesis in skeletal muscle, leading to greater rates of fatty acid oxidation. 231 Metabolic dysregulation, especially in the situation where the rate of fatty acid uptake exceeds the rate of fatty acid oxidation, 232, 233 leads to a wide range of disturbances that have been attributed to mitochondrial dysfunction, 234, 235 and which culminate in triglyceride accumulation. 172, 236 Glucose and its metabolites also have multiple functions in the cardiac myocyte that extend beyond the role of glucose as an energy source. Failure to adequately control levels of intracellular glucose metabolites has been implicated in the development of insulin resistance and in the generation of reactive oxygen species (ROS). Compared to the liver, 237 relatively little is known about the effects of glucose metabolites on gene expression in the heart. Through investigations of the glucose/carbohydrate response elements (GlRE/ChoRE) in the promoter regions of various glucose-regulated genes, a number of candidate transcription factors have been identifi ed that are believed to be involved in glucose-mediated gene expression. In the liver and in fat cells upstream stimulatory factor (USF), stimulatory protein-1 (Sp1), and sterol regulatory element binding protein-1 (SREBP1) play a role in glucose sensing, 238 and it is reasonable to assume that the same transcription factors play similar roles in the heart.
229
The Metabolic Syndrome A discussion of cardiac metabolism is incomplete without a discussion of the metabolic syndrome (MS). The metabolic syndrome is not a disease but rather a constellation of physiognomic, physiologic, and pathologic features that refl ect the altered metabolic state of insulin resistance-a "metabolic axis of evil." The constellation exhibits three characteristics: (1) it clusters within individuals; (2) it predicts the future development of type 2 diabetes mellitus; and (3) it predicts the development of atherosclerosis and the occurrence of ischemic events. The components of the MS may then be grouped into three categories: (1) disordered energy metabolism; (2) infl ammation; and (3) abnormalities of the circulation (including an increase in systemic vascular resistance and induction of a prothrombotic state).
Traditionally, the MS is a way of viewing the association between insulin resistance, altered fuel metabolism, and atherosclerotic cardiovascular disease, particularly coronary heart disease. To the epidemiologist, the metabolic syndrome is the set of attributes that share the property of being risk factors both for accelerated atherosclerosis and for development of type 2 diabetes mellitus. 239 To the pathophysiologist, the metabolic syndrome consists of those metabolic and pathophysiologic consequences of visceral obesity and insulin resistance that are related to development of accelerated atherosclerosis. The fact that the components of the MS cluster within individuals implies that they are physiologically related, although the underlying causes are not exactly known. To the clinician it has long been known that the MS, like type 2 diabetes mellitus, increases the risk for coronary, peripheral, and cerebral atherosclerotic/ occlusive events. The new concept of cardiometabolic risk underscores that it precedes the appearance of hyperglycemia, at least for individuals who later develop type 2 diabetes mellitus. Consequently, these individuals will benefi t from aggressive management of all known risk factors.
Obesity, type 2 diabetes, and the metabolic syndrome are multifactorial risk factors for cardiovascular diseases of considerable heterogeneity. 240 However, whereas the diagnostic criteria for obesity and for type 2 diabetes are defi ned by large epidemiologic studies, the criteria for the metabolic syndrome are not as clear-cut. 241, 242 The only consensus is that cardiovascular disease (CVD) is a major clinical outcome of the metabolic syndrome. 242 Over the years there have been a number of attempts to develop standardized criteria for the diagnosis of MS. In 1998 the World Health Organization (WHO) proposed a defi nition stating that individuals with MS show evidence of insulin resistance plus at least two of four other factors: hypertension, hyperlipidemia, obesity, and microalbuminuria. 243 In 2001, the National Cholesterol Education Program's (NCEP) Adult Treatment Panel III (ATP III) suggested a more practical defi nition for the metabolic syndrome (Table 50 .1). At least three of the following fi ve factors need to be present for the diagnosis of the metabolic syndrome: increased waist circumference, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, hypertension, and a fasting glucose of 110 mg/dL (now 100 mg/dL) or higher. This defi nition is easier to use in clinical practice than the WHO guidelines. No matter what the defi nition, the term refers to a state of metabolic and circulatory dysregulation of the body. The term metabolic syndrome is somewhat of a misnomer because it fails to refl ect the profound metabolic dysregulation occurring at the organ level (e.g., muscle and liver). More appropriate would be the term dysmetabolic syndrome, which we prefer because it includes the connotation of dysregulated fuel supply due to profound changes in fuel homeostasis. As the result of an oversupply of substrate in the heart, the heart fails in the midst of plenty. For the heart in the pathophysiologic state of diabetes mellitus, we have proposed three possible mechanisms for the metabolic maladaptation and contractile failure of the heart 114,229 -lipotoxicity, glucotoxicity, and glucolipotoxicity-none of which has been completely elucidated, although certain pharmacologic agents, especially insulin sensitizing agents, hold the promise of reversing the adverse effects of metabolic dysregulation. 201, 202, 244 We have shown that the progression of diabetes is, paradoxically, associated with a decline in messenger RNA (mRNA) transcript levels of PPAR-α. 165, 245 It is reasonable to assume that the continued exposure to high fatty acid levels will accelerate lipid accumulation of triglycerides (akin to a spillover of excess fuel). Like a sentinel, lipid accumulation also is a feature of the failing human heart 171 and is associated with a broad range of cellular and metabolic derangements collectively called lipotoxicity. 172, 246 Possible mechanisms causing a decline in contractile function of the "lipotoxic heart" include the inhibition of the adenine nucleotide translocator by fatty-acyl-CoA, the upregulation of tumor necrosis factor-α (TNF-α), increased ceramide levels, ROS accumulation, inducible nitric oxide synthase (iNOS) induction, chronic activation of PKCs, myosin isoform switches, 247 downregulation of MEF2C regulated genes, 248 cytochrome C release, 249 and apoptosis. 201 Interestingly, the heart's ability to secrete lipoproteins is inversely related to pathologic lipid accumulation. 250 In addition, the ability to secrete lipoproteins protects the heart against the development of cardiomyopathy in a diabetes model. 251 Lastly, in rodent models of lipotoxicity, the administration of leptin decreases nonadipose tissue lipid accumulation and ameliorates lipotoxicity. 252 Thus, a wide array of potentially reversible disturbances of fatty acid and lipid metabolism is involved in the phenomenon of lipotoxicity.
Excessive glucose metabolic accumulation is also associated with various cardiac pathologies. Although studied mainly in the vasculature, the four main mechanisms proposed for hyperglycemia-induced diabetic complications 252 are likely to be operative in the cardiomyocyte as well. The four hypotheses are increased polyol pathway fl ux (via aldose reductase), increased intracellular formation of advanced glycation end-products (AGE), and AGE-induced ROS generation, activation of PKC mostly through activation by the lipid second messenger diacylglycerol (DAG), and increased fl ux through the hexosamine biosynthetic pathway. 252 As mentioned, many of these hypotheses have thus far been tested only in vascular tissue and await further confi rmation in cardiomyocytes. However, it is already known that O-linked β-N-acetylglucosamine (O-GlcNAc) modifi es many different nuclear and cytoplasmic proteins and that O-GlcNAc plays an important role in signal transduction. 253 Young et al. 229 have proposed a "spillover" of intermediates of glucose metabolism into the hexosamine biosynthetic pathway and into the pentose phosphate pathway. The concept of metabolic regulation of cell signaling is attractive in light of possible crosstalk between glucose signaling and fatty acid signaling involving dysregulation of the 5′AMP-activated protein kinase AMPK/malonyl-CoA fuel sensing and signaling network. 254 In this context Randle et al.'s 255 "glucosefatty acid cycle" comes again into play. The phenomenon describes the inactivation of pyruvate dehydrogenase by fatty acids, which is greater than the inhibition of glycolysis and glucose uptake in heart.
The "metabolic axis of evil" is a multifactorial, heterogeneous group of risk factors for the development of cardiovascular disease. Metabolic dysregulation of glucose and fatty acid metabolism involves many organs of the body, including the heart. Lipid metabolism does not stop in the arterial wall. In spite of its remarkable adaptability, the heart fails in the midst of plenty. We propose the following scenario: Elevated circulatory fatty acid levels result in activation of PPAR-α in the cardiomyocyte, increased fatty acid oxidation, and decreased pyruvate oxidation (the Randle phenomenon). The dissociation of glycolytic fl ux and pyruvate oxidation results in the accumulation of glycolytic intermediates that activate glucose sensitive transcription factors. The heart loses its capacity to switch from one substrate to another, and with additional stresses placed on the heart (e.g., hypertension, ischemia), metabolic maladaptation will occur. A vicious cycle is set into motion when substrate availability exceeds substrate oxidation by the heart. In principle, this phenomenon was already recognized by Rudolph Virchow's 256 textbook on cellular pathology when he described "fatty atrophy" as a "true metamorphosis of the heart muscle cell." It appears that Virchow already recognized morphologic correlates of insulin resistance in the heart beyond the arterial wall.
Metabolic Targets to Improve Cardiac Function
Myocardial energy substrate metabolism has recently received the attention of the pharmaceutical industry, especially with studies of the group of agents that are supposed to shift the heart's energy supply from oxidation of fatty acids to the energetically more effi cient oxidation of glucose and lactate in the postischemic heart. This shift can be brought about by restoring insulin sensitivity of the heart, by inhibiting fatty acid oxidation at various levels, or by activating the pyruvate dehydrogenase complex. A case in point is glucose-insulin-potassium (GIK) in the treatment of cardiogenic shock after hypothermic ischemic arrest of the heart. 147 Other examples include drugs such as etomoxir, ethyl-2-tetradecyl glycidate, and oxfenicine, drugs that inhibit long-chain fatty acid oxidation by inhibiting the entry of long-chain fatty acids into the mitochondria at the level of carnitine palmitoyl transferase-I (CPT-I). 257, 258 CPT-I has become a target for pharmacologic intervention in the postischemic reperfused heart in which rates of fatty acid oxidation are relatively high and contractile function is (reversibly) impaired. Etomoxir has also generated interest as a drug that may improve energy effi ciency in heart failure. 259 However, the therapeutic window of etomoxir seems narrow, because in skeletal muscle, CPT-I inhibition leads to excess triglyceride accumulation and lipotoxicity. 230 The piperazine compound trimetazidine belongs to the group of partial fatty acid oxidation (PFox) inhibitors and is widely used in France as an antianginal drug. 260 Trimetazidine is thought to inhibit long-chain fatty acid oxidation by inhibiting one of the terminal steps in the β-oxidation pathway, 261 resulting in a switch of energy substrate preference and improved exercise duration in patients with chronic, stable angina who were already receiving other antianginal therapy. 262 Ranolazine decreases fatty acid oxidation, promotes glucose oxidation, and acts indirectly by increasing pyruvate dehydrogenase complex activity. 263 The exact mechanism of action of PFox inhibitors, however, is still unknown.
The list of drugs targeting intermediary metabolism for the treatment of cardiac dysfunction also includes insulinsensitizing agents such as thiazolidinediones, glucogen-like peptide-1 (GLP1), 264 as well as propionyl L-carnitine, an anaplerotic agent that also raises the level of free coenzyme A. The opportunities for regeneration of normal cardiac myocyte function through metabolic interventions seem at present unlimited.
Summary
Myocardial metabolism is an integral part of the function of the heart as consumer and provider of energy. The bulk of the energy for contraction of the heart comes from oxidative phosphorylation of ADP. However, "energy reserves" in the form of ATP or phosphocreatine are very small. A vast network of highly regulated metabolic pathways regulates energy substrate metabolism and matches demand and supply with precision. Energy transfer is impaired in the failing heart, and restoration of effi cient energy substrate metabolism is an emerging target for the treatment of the failing heart.
